Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicenter Phase II Study

NCT06218810 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06218810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06218810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer: A Single-Arm, Open-Label, Multicenter Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2024
Completion date
December 31, 2026
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cadonilimab, metastatic colorectal cancer, microsatellite stable colorectal carcinoma, ras mutation